RENO, Nev., Sept. 26, 2012 /PRNewswire/ -- First Warning
Systems, Inc. announces the addition of Nola Masterson, to the First Warning Advisory
Board as Senior Business and Strategy Advisor. Mrs. Master
provides C-level expertise to FWS, focusing on strategic inputs and
guidance. Ms. Masterson is a biotechnology industry leader
and forward thinker with more than 35 years of business experience
in the life sciences industry and in venture capital investment.
Currently, she is Managing Director of Science Futures Management
Company, LLC. (sciencefuturesinc.com), a 30 year old investment and
advisory firm. From 2000 to 2005, she was a Venture Partner
with TVM Capital GmbH, one of the first and largest venture capital
firms in Germany. She sourced and
invested in three companies and built out their San Francisco office.
She was a co-founder and President of Sequenom, Inc., a DNA
sequencing company which went public on Nasdaq in 2000, and wrote
the first business plans for IDEC and Insight Vision, as a
consultant to Kleiner Perkins
Caufield & Byers, and for ReSound, with Dr. Rodney Perkins, the founder. She was the
first biotech analyst on Wall Street for Drexel Burnham and Merrill Lynch. She was
the creator of two important conferences, The BioTech Meeting in
Laguna Nigel and The Biopharmaceutical Conference in Europe. She and Cynthia Robbins Roth started the publication
BioVenture View, which became the first online newsletter about
biotechnology.
Ms. Masterson is Chairwoman of the Board of Directors of Repros
Therapeutics Inc. and serves on the Board of Directors of Generex
Biotechnology Inc. She serves on the Audit Committee and
Compensation Committee of both companies. She is Chairwoman
Emeritus of the BayBio Institute, a non-profit organization serving
the Northern California life
sciences industry by focusing on best practices, entrepreneurship,
workforce development and science education, and also serves on the
Board of Advisors to Astia, a non-profit organization dedicated to
advancing women entrepreneurs. She also is on the Board of
Advisors of the Professional Women's Healthcare Alliance and of
BioAgenda. She is a graduate of the Stanford Law School Board
of Directors College course.
In 2003, she was included in Irish
America magazine's annual "Business 100" and received the
Alumni Achievement Award from Marymount
College at Fordham University in 2004.
About First Warning Systems
First Warning Systems, (FWS) founded in 2008, is based in
Reno, NV. FWS's principal
shareholder is Lifeline Biotechnologies, Inc (OTC Market: LLBO).
FWS holds the exclusive development, manufacturing and marketing
worldwide license from Lifeline, to commercialize the intellectual
property. The FWS product line is a device and process that detects
breast tissue abnormalities leading to health risk assessment and
management and potentially, breast cancer. Three clinical trials
with over 650 participants have achieved proof of concept and
superior outcomes when compared to other diagnostic protocols.
FWS is planning a final, limited clinical trial and a 510k
device classification to validate the fourth generation of the FWS
product. FWS is preparing to apply for a Euro CE Mark to market in
the UK, EU and Russia markets. See
FWS' video, "Breast Cancer Tumor Progression" at
www.firstwarningsystems.com
For more information, contact: Jim Holmes, CEO
775-852-3222 jholmes@firstwarningsystems.com
SOURCE First Warning Systems, Inc.